NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

CompletedPhase 2

Sponsor: Genzyme, a Sanofi Company

Conditions: Thyroid Cancer

Interventions: ZD6474 (vandetanib)

Countries: United States, Australia, Canada, Italy, Netherlands, Romania, Spain, Switzerland

This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option is available.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Provision of written informed consent
* Previously confirmed histological diagnosis of locally advanced or metastatic hereditary medullary thyroid carcinoma without standard therapeutic options
* Aged 18 or over and a life expectancy of more than 12 weeks

Exclusion Criteria:

* The last dose of prior chemo/radiation received less than 4 weeks before the start of study therapy
* Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age, history of arrhythmia

Locations (9)

Little Rock, Arkansas, United States
Boston, Massachusetts, United States
St Leonards, Australia
Sherbrooke, Quebec, Canada
Pisa, Italy
Utrecht, Netherlands
Bucharest, Romania
Madrid, Spain
Basel, Switzerland